Stockscreener 앱 받기
175.52
2.64%
-5.03
전일 마감가:
$180.55
열려 있는:
$181
하루 거래량:
406.50K
Relative Volume:
0.34
시가총액:
$17.66B
수익:
$3.10B
순이익/손실:
$668.60M
주가수익비율:
26.98
EPS:
6.5044
순현금흐름:
$831.30M
1주 성능:
+0.87%
1개월 성능:
+9.27%
6개월 성능:
+29.45%
1년 성능:
+30.28%
1일 변동 폭
$174.21
$181.18
1주일 범위
$171.14
$181.18
52주 변동 폭
$122.14
$181.18
뉴로크린 바이오사이언시스 Stock (NBIX) Company Profile
명칭
Neurocrine Biosciences Inc
전화
(858) 617-7600
주소
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
175.65 | 18.15B | 3.10B | 668.60M | 831.30M | 6.5044 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 53.04B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.775 | 42.76B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.88 | 38.54B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.84 | 31.48B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
543.22 | 23.45B | 3.17B | 1.29B | 1.01B | 27.09 |
뉴로크린 바이오사이언시스 Stock (NBIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | 개시 | Citigroup | Buy |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2025-04-15 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-14 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 재개 | Citigroup | Neutral |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-08-21 | 재확인 | Mizuho | Neutral |
| 2023-07-24 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-30 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-02-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-09-26 | 개시 | Wells Fargo | Equal Weight |
| 2022-06-06 | 재개 | Jefferies | Buy |
| 2022-03-03 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-01-18 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | 개시 | BMO Capital Markets | Underperform |
| 2021-11-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-08-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-05-06 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-02-02 | 개시 | Raymond James | Outperform |
| 2020-09-30 | 개시 | The Benchmark Company | Hold |
| 2020-08-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-06-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-06-09 | 개시 | Wedbush | Outperform |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-24 | 개시 | William Blair | Outperform |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-13 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-05 | 개시 | Guggenheim | Neutral |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-02-06 | 재확인 | BofA/Merrill | Buy |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-11-21 | 개시 | Canaccord Genuity | Buy |
모두보기
뉴로크린 바이오사이언시스 주식(NBIX)의 최신 뉴스
Did Neurocrine’s (NBIX) CRENESSITY Push Into Infants Just Recast Its Rare-Disease Strategy? - simplywall.st
Form 4 Neurocrine Biosciences Inc For: 9 July By Investing.com - Investing.com Canada
Neurocrine Biosciences chief regulatory officer sells $2.6m stock By Investing.com - Investing.com Canada
Neurocrine (NBIX) officer sells 14,571 shares under Rule 10b5-1 plan - Stock Titan
Form 144 NEUROCRINE BIOSCIENCES For: 9 July By Investing.com - Investing.com Canada
10,000 NBIX shares listed for sale; recent Darin Lippoldt 10b5-1 trades (NBIX) - Stock Titan
Neurocrine's July 30 earnings call is scheduled for 4:30 p.m. ET - Stock Titan
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results - The Independent Record
Neurocrine Biosciences stock stays supported by a growing movement disorder portfolio - AD HOC NEWS
ETFs Investing in Neurocrine Biosciences, Inc. Stocks - TradingView
Neurocrine Biosciences (NBIX) Stock Looks Fair On Earnings But Pricey Versus Biotechs - Yahoo Finance
Neurocrine Biosciences (NBIX) Stock Looks Reasonable After Its 90% Run - simplywall.st
Neurocrine Biosciences (NBIX) Could Be 8% Undervalued Following New Phase 2 Study - Yahoo Finance
Neurocrine Biosciences (NBIX) Starts Phase 2 CAH Study In Children Under 4 - Yahoo Finance
Reasons why investors should consider betting on Neurocrine stock - MSN
Neurocrine (NBIX) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Tardive Dyskinesia Market to Grow Rapidly at a CAGR of 8.1% During the Forecast Period (2026-2036) | DelveInsight - Yahoo Finance
Neurocrine Biosciences outlines its neurology focus as a mid-cap biotech name - AD HOC NEWS
Insider option exercise and 10b5-1 sales at NBIX (NBIX) - Stock Titan
Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities - AOL.com
Neurocrine Biosciences stock hits all-time high at 176.1 USD - Investing.com
Neurocrine Biosciences stock hits all-time high at 176.1 USD By Investing.com - Investing.com UK
Neurocrine Biosciences stock and its role in neurological treatments - AD HOC NEWS
RBC Capital Adjusts Neurocrine Biosciences Price Target to $195 From $183, Maintains Outperform Rating - Moomoo
Neurocrine Biosciences, Inc. (NBIX): Analyst Consensus and Growth Potential with a 12% Upside - DirectorsTalk Interviews
Enterprise value to EBIT forward of Neurocrine Biosciences, Inc. – NASDAQ:NBIX - TradingView
Neurocrine Biosciences Inc (NASDAQ:NBIX) Shines in the "Little Book That Makes You Rich" Screen - ChartMill
NBIXNeurocrine Biosciences Inc Options - Finviz
What Neurocrine Biosciences (NBIX)'s Index Removal and INGREZZA Momentum Means For Shareholders - Sahm
Neurocrine Biosciences Inc (NBIX) Stock Up 3.9% and Still Underv - GuruFocus
Neurocrine Biosciences: Why I Am Upholding A Buy Rating After M&A Deal For Soleno (NBIX) - Seeking Alpha
Zacks.com featured highlights include Neurocrine Biosciences, MYR Group, Block, Delek US Holdings and Dycom Industries - Yahoo Finance
Neurocrine (NBIX) Reports Clinically Meaningful Benefits in 94% of Patients Treated for Tardive Dyskinesia - Yahoo Finance
Neurocrine starts phase 2 trial of crinecerfont in infants with CAH - Investing.com
Neurocrine tests CRENESSITY in infants and toddlers with rare CAH - Stock Titan
Neurocrine Biosciences (NBIX) Is Up 6.46% in One Week: What You Should Know - Yahoo Finance
Neurocrine Biosciences Inc (NASDAQ:NBIX) Shows Strong Growth and Technical Breakout Setup - ChartMill
Price to book forward of Neurocrine Biosciences, Inc. – NASDAQ:NBIX - TradingView
Neurocrine (NBIX) legal chief exercises options and sells 10,000 shares - Stock Titan
Neurocrine Biosciences' Ingrezza Momentum Seen Supporting 2026 Guidance Upgrade, UBS Says - Moomoo
Price to book forward of Neurocrine Biosciences, Inc. – MIL:1NBIX - TradingView
UBS Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $208 - Moomoo
9,800-share Form 144 filed for NBIX (NASDAQ: NBIX) - Stock Titan
Bull of the Day: Neurocrine Biosciences (NBIX) - TradingView
Neurocrine Biosciences and Ryanair have been highlighted as Zacks Bull and Bear of the Day - The Globe and Mail
Neurocrine Biosciences stock hits all-time high at 169.62 USD By Investing.com - Investing.com Nigeria
Neurocrine Biosciences stock hits all-time high at 169.62 USD - Investing.com
Neurocrine Biosciences, Inc.(NasdaqGS: NBIX) dropped from Russell 1000 Dynamic Index - marketscreener.com
Neurocrine Biosciences (NBIX) Is Up 6.5% After CRENESSITY Shows Broad CAH Benefits at ENDO 2026 – Has The Bull Case Changed? - Yahoo Finance
Neurocrine Biosciences (NBIX) Unveils New CRENESSITY Data For Classic CAH And Rare Subtype - Yahoo Finance
Neurocrine Biosciences (NBIX) Showed New CRENESSITY Data, Is The Stock Still Cheap? - simplywall.st
뉴로크린 바이오사이언시스 (NBIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
뉴로크린 바이오사이언시스 주식 (NBIX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Delaet Ingrid | Chief Regulatory Officer |
Jul 07 '26 |
Option Exercise |
103.52 |
3,401 |
352,072 |
19,626 |
| Delaet Ingrid | Chief Regulatory Officer |
Jul 08 '26 |
Option Exercise |
103.52 |
2,737 |
283,334 |
18,962 |
| Delaet Ingrid | Chief Regulatory Officer |
Jul 09 '26 |
Sale |
178.72 |
8,433 |
1,507,135 |
16,225 |
| Delaet Ingrid | Chief Regulatory Officer |
Jul 07 '26 |
Sale |
178.57 |
3,401 |
607,305 |
16,225 |
| Delaet Ingrid | Chief Regulatory Officer |
Jul 08 '26 |
Sale |
178.54 |
2,737 |
488,672 |
16,225 |
0.84%
0.28%
자본화:
|
볼륨(24시간):